Contraindications
Ocular or Periocular Infections:
YUTIQ is contraindicated in patients with active or suspected ocular or periocular
infections including most viral disease of the cornea and conjunctiva including active
epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella,
mycobacterial infections and fungal diseases.
Hypersensitivity:
YUTIQ is contraindicated in patients with known hypersensitivity to any components of
this product.
Warning and precautions
Intravitreal Injection-related Effects:
Intravitreal injections, including those with YUTIQ, have been associated with
endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and
choroidal or retinal detachments. Hypotony has been observed within 24 hours of
injection and has resolved within 2 weeks. Patients should be monitored following the
intravitreal injection.
Steroid-related Effects:
Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts,
increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the
establishment of secondary ocular infections due to bacteria, fungi, or viruses.
Corticosteroids are not recommended to be used in patients with a history of ocular
herpes simplex because of the potential for reactivation of the viral infection.
Risk of Implant Migration:
Patients in whom the posterior capsule of the lens is absent or has a tear are at risk
of implant migration into the anterior chamber.
Adverse reactions
In controlled studies, the most common adverse reactions reported were cataract
development and increases in intraocular pressure.
Please see full
Prescribing Information.
